MAPT and Alzheimer disease: Studies in clinical cohorts and rats have suggested that BDZs improve cognitive function in AD by activating inhibitory GABAergic neurons, exerting anti-inflammatory and neuroprotective effects and inhibiting Aβ aggregation and tau protein phosphorylation [82].